CA Patent

CA2726317A1 — Inhibitors of akt activity

Assigned to MSD KK · Expires 2009-12-10 · 16y expired

What this patent protects

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms, preferably Akt1. The invention also provides for compositions comprising such inhibitory co…

USPTO Abstract

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms, preferably Akt1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity especially Akt1 by administering the com-pound to a patient in need of treatment of cancer.

Drugs covered by this patent

Patent Metadata

Patent number
CA2726317A1
Jurisdiction
CA
Classification
—
Expires
2009-12-10
Drug substance claim
No
Drug product claim
No
Assignee
MSD KK
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.